HEBEI, China | July 9, 2026
WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has announced that its MFG8 drug substance manufacturing facility in Hebei has successfully passed the U.S. Food and Drug Administration (FDA) Pre-License Inspection (PLI), marking another major regulatory milestone for the company. The successful inspection enables the facility to support the commercial manufacturing of a potential blockbuster autoimmune therapy, further strengthening WuXi Biologics’ position as a trusted global manufacturing partner for innovative biologics. Conducted over seven days by three FDA inspectors, the comprehensive inspection evaluated the facility’s quality management systems, Good Manufacturing Practice (GMP) compliance, and drug substance manufacturing operations. The successful outcome reinforces the company’s long-standing reputation for regulatory excellence, quality assurance, and global manufacturing reliability, while demonstrating its continued commitment to delivering high-quality biologics that meet stringent international regulatory standards.
FDA Pre-License Inspection Validates World-Class GMP Manufacturing
The successful FDA Pre-License Inspection (PLI) confirms that WuXi Biologics’ MFG8 facility meets rigorous regulatory expectations required for commercial biologics manufacturing. As a critical component of the company’s expanding global manufacturing network, MFG8 is equipped with twelve 4,000-liter single-use bioreactors utilizing WuXi Biologics’ innovative “scale-out” manufacturing strategy, allowing flexible commercial production ranging from 4,000L to 20,000L while maintaining operational efficiency and manufacturing consistency.
The facility combines advanced automation, digital manufacturing platforms, and modern process technologies to deliver reliable commercial-scale production for global biopharmaceutical partners. Beyond manufacturing excellence, MFG8 also incorporates state-of-the-art sustainability initiatives, including a rooftop photovoltaic system, resource recycling programs, carbon reduction technologies, and environmentally responsible facility design, reflecting the company’s commitment to supporting sustainable biologics manufacturing alongside operational excellence.
Regulatory Excellence Strengthens Global Commercial Manufacturing Capabilities
Advertisement
The latest FDA approval further expands WuXi Biologics’ impressive regulatory compliance record and highlights the strength of its integrated global quality management system. As of the end of 2025, the company had successfully completed 46 global regulatory inspections, including 22 inspections conducted by the FDA and the European Medicines Agency (EMA), while securing 136 manufacturing facility license approvals worldwide. Notably, WuXi Biologics maintains an industry-leading 100% FDA Pre-License Inspection pass rate, underscoring its consistent ability to satisfy the highest international manufacturing standards.
In addition, the company has successfully completed more than 1,800 GMP quality audits conducted by global biopharmaceutical clients, including over 230 audits by European Union Qualified Persons (QPs). Today, WuXi Biologics operates 25 drug substance manufacturing facilities and 18 drug product facilities across its expanding global network, providing end-to-end development and commercial manufacturing support for a broad portfolio of innovative biologics spanning oncology, autoimmune diseases, rare diseases, infectious diseases, and other therapeutic areas.
Advanced CRDMO Infrastructure Accelerates Global Biologics Commercialization
The FDA approval of MFG8 reinforces WuXi Biologics’ leadership in global biologics manufacturing and demonstrates the growing importance of high-quality CRDMO partners in accelerating access to innovative therapies. With more than 13,000 employees across China, the United States, Ireland, Germany, and Singapore, the company currently supports 982 integrated client projects, including 78 Phase III programs and 25 commercial manufacturing projects, representing one of the industry’s largest biologics development portfolios. By integrating digital technologies, predictive analytics, advanced manufacturing platforms, and scalable biologics production capabilities, WuXi Biologics enables pharmaceutical and biotechnology companies to move therapies efficiently from discovery through commercialization.
The successful FDA inspection of MFG8 not only strengthens commercial readiness for an important autoimmune biologic therapy, but also reinforces WuXi Biologics’ reputation as a globally trusted manufacturing partner capable of supporting next-generation biologics with exceptional GMP compliance, regulatory quality, manufacturing flexibility, and sustainable operations. As demand for complex biologics continues to expand worldwide, the company’s investment in advanced manufacturing infrastructure positions it to play a critical role in accelerating the delivery of life-changing medicines to patients around the globe.
Source: WuXi Biologics press release
